{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:27:44Z","timestamp":1793683664752,"version":"4.5.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ijcard.2022.10.152","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T12:17:40Z","timestamp":1666700260000},"page":"412-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period"],"prefix":"10.1016","volume":"370","author":[{"given":"Rawan O.","family":"Almadfaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia R.","family":"Wigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Hincapie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff J.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2022.10.152_bb0015","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"International society of hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0025","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults","volume":"71","author":"Whelton","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0030","series-title":"StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2022","article-title":"Angiotensin converting enzyme inhibitors (ACEI)","author":"Herman","year":"2022"},{"key":"10.1016\/j.ijcard.2022.10.152_bb0035","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/VHRM.S23468","article-title":"Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk","volume":"7","author":"Farsang","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7326\/0003-4819-148-1-200801010-00189","article-title":"Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension","volume":"148","author":"Matchar","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0045","first-page":"47","article-title":"Hypertension management: an update","volume":"3","author":"Nguyen","year":"2010","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.ijcard.2022.10.152_bb0050","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/ajh\/hpx085","article-title":"Current trends of hypertension treatment in the United States","volume":"30","author":"Shah","year":"2017","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0055","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.07.026","article-title":"Antihypertensive drugs","volume":"124","author":"Laurent","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008731","article-title":"Trends in Healthcare Expenditures Among US Adults With Hypertension: National Estimates, 2003-2014","volume":"7","author":"Kirkland","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0070","doi-asserted-by":"crossref","first-page":"707102","DOI":"10.3389\/fcvm.2021.707102","article-title":"Epidemiology of geographic disparities of myocardial infarction among older adults in the United States: analysis of 2000-2017 medicare data","volume":"8","author":"Yu","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0075","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/jamacardio.2020.3654","article-title":"Trends in the prevalence of self-reported heart failure by race\/ethnicity and age from 2001 to 2016","volume":"5","author":"Rethy","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0080","first-page":"S163","article-title":"All-cause costs increase exponentially with increased chronic kidney disease stage","volume":"23","author":"Golestaneh","year":"2017","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ijcard.2022.10.152_bb0085","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/clc.23585","article-title":"Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans","volume":"44","author":"Lam","year":"2021","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0090","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11906-013-0353-4","article-title":"Generic drugs for hypertension: are they really equivalent?","volume":"15","author":"Cooper-DeHoff","year":"2013","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0095","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1001\/jamainternmed.2019.3107","article-title":"Potential Medicare savings from generic substitution and therapeutic interchange of ACE inhibitors and angiotensin-II-receptor blockers","volume":"179","author":"Growdon","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0100","series-title":"Generic Drug Facts","year":"2021"},{"key":"10.1016\/j.ijcard.2022.10.152_bb0105","first-page":"275","article-title":"Trends in utilization, spending, and prices of smoking-cessation medications in medicaid programs: 25 years empirical data analysis, 1991-2015","volume":"11","author":"Yue","year":"2018","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.ijcard.2022.10.152_bb0110","first-page":"3","article-title":"Drug expenditure, price, and utilization in the U.S. Medicaid: a trend analysis for SSRI and SNRI antidepressants from 1991 to 2018","volume":"24","author":"Alrasheed","year":"2021","journal-title":"J. Mental Health Policy Econ."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0115","first-page":"11","article-title":"Causes of Medicaid expenditure growth","volume":"16","author":"Wade","year":"1995","journal-title":"Health Care Financ. Rev."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0120","series-title":"BMC Health Services Research","first-page":"327","article-title":"Intergenerational enrollment and expenditure changes in medicaid: trends from 1991 to 2005","volume":"12","author":"Patrick","year":"2012"},{"key":"10.1016\/j.ijcard.2022.10.152_bb0125","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/HYPERTENSIONAHA.108.113357","article-title":"Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988\u20131994 and 1999-2004","volume":"52","author":"Cutler","year":"2008","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.ijcard.2022.10.152_bb0130","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/bcp.13692","article-title":"Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: a UK population-based study","volume":"84","author":"Mahmoudpour","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0135","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.ijcard.2022.10.152_bb0145","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/hec.2935","article-title":"Therapeutic substitution post-patent expiry: the cases of ACE inhibitors and proton pump inhibitors","volume":"23","author":"Vandoros","year":"2014","journal-title":"Health Econ."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0150","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0155","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/HJH.0000000000000130","article-title":"Medication persistence and the use of generic and brand-name blood pressure-lowering agents","volume":"32","author":"Corrao","year":"2014","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10654-015-0104-8","article-title":"Generic versus brand-name drugs used in cardiovascular diseases","volume":"31","author":"Manzoli","year":"2016","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0165","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/eci.12326","article-title":"Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study","volume":"44","author":"Corrao","year":"2014","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0170","author":"(ASPA) ASfPA"},{"key":"10.1016\/j.ijcard.2022.10.152_bb0180","doi-asserted-by":"crossref","first-page":"e0249453","DOI":"10.1371\/journal.pone.0249453","article-title":"Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims","volume":"16","author":"Clement","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2022.10.152_bb0185","doi-asserted-by":"crossref","first-page":"430","DOI":"10.5414\/CP202243","article-title":"Trends and patterns of five antihypertensive drug classes between 2007 and 2012 in China using hospital prescription data","volume":"53","author":"Xu","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ajh\/hpab137","article-title":"Prescription patterns for the use of antihypertensive drugs for primary prevention among patients with hypertension in the United Kingdom","volume":"35","author":"Jiao","year":"2022","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0195","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMe0801925","article-title":"ACE inhibitors in cardiovascular disease--unbeatable?","volume":"358","author":"McMurray","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.10.152_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026139","article-title":"Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in the Netherlands\u2013a Markov model","volume":"6","author":"Adarkwah","year":"2011","journal-title":"PLoS One"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322016631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322016631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:00:18Z","timestamp":1759093218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527322016631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"alternative-id":["S0167527322016631"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.10.152","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.10.152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}